Roots Analysis has done a detailed
study on Cancer Biomarkers
Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key
aspects of the industry and identifying key future growth opportunities.
To order this 370+ page report, which features 190+ figures
and 180+ tables, please visit this https://www.rootsanalysis.com/reports/253/request-sample.html
Key
Market Insights
§
§
§
§
§
§
§
§
§
For
more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html
Table
of Contents
1. PREFACE
1.1. Scope
of the Report
1.2. Research
Methodology
1.3. Chapter
Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter
Overview
3.2. Cancer
Immunotherapy
3.2.1. Cancer
Immunotherapy Biomarkers
3.2.2. Identification
of a Candidate Biomarker
3.2.3. Need
for Novel Cancer Biomarkers
3.3. Tumor
Mutation Burden (TMB)
3.3.1. Overview
3.3.2. Variation
of TMB across Multiple Indications
3.3.3. Methods
for Measurement of TMB
3.3.4. Factors
Affecting Measurement of TMB
3.3.5. Initiatives
for Assessment of TMB as a Potential Biomarker
3.4. Microsatellite
Instability / Mismatch Repair Deficiency (MSI / MMR)
3.4.1. Overview
3.4.2. Variation
of MSI across Multiple Indications
3.4.3. Methods
of Measurement of MSI
3.5. Tumor
Infiltrating Lymphocytes and Other Novel Biomarkers
4 CURRENT MARKET LANDSCAPE
4.1. Chapter
Overview
4.2. Cancer
Biomarkers Testing Services: Overall Market Landscape
4.2.1. Analysis
by Year of Establishment
4.2.2. Analysis
by Company Size
4.2.3. Analysis
by Geographical Location
4.2.4. Analysis
by Test Availability
4.2.5. Analysis
by Type of Biomarker
4.2.6. Analysis
by Application Area
4.2.7. Analysis
by Disease Indication
4.2.8. Analysis
by Analytical Technique Used
4.2.9. Analysis
by Turnaround Time
4.2.10. Analysis
by Sample Input
4.2.11. Analysis
by Nucleic Acid Tested
4.2.12. Key
Players: Analysis by Type of Biomarker
4.3. TMB
Tests
4.3.1. Analysis
by Application Area
4.3.2. Analysis
by Disease Indication
4.3.3. Analysis
by Analytical Technique Used
4.3.4. Analysis
by Turnaround Time
4.4. MSI
/ MMR Tests
4.4.1. Analysis
by Application Area
4.4.2. Analysis
by Disease Indication
4.4.3. Analysis
by Analytical Technique Used
4.4.4. Analysis
by Turnaround Time
4.5. TIL-based
Tests
4.5.1. Analysis
by Application Area
4.5.2. Analysis
by Disease Indication
4.5.3. Analysis
by Analytical Technique Used
4.5.4. Analysis
by Turnaround Time
5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter
Overview
5.2. Product
Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Tests
for the Assessment of TMB
5.2.2. Tests
for the Assessment of MSI / MMR
5.2.3. Tests
for the Assessment of TILs
6 COMPANY PROFILES
6.1. Chapter
Overview
6.2. Dr
Lal PathLabs
6.2.1. Company
Overview
6.2.2. Financial
Information
6.2.3. Product
/ Service Portfolio
6.2.3.1. Biomarkers
Testing Portfolio
6.2.3.1.1. Microsatellite Instability (MSI) by PCR
6.2.3.1.2. OncoPro NCCN Lung Cancer Panel (*9 Genes
*MSI)
6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with
MSI
6.2.4. Recent
Developments and Future Outlook
6.3. Foundation
Medicine
6.3.1. Company
Overview
6.3.2. Financial
Information
6.3.3. Product
/ Service Portfolio
6.3.3.1. Biomarkers
Testing Portfolio
6.3.3.1.1. FoundationOne CDx
6.3.3.1.2. FoundationOne Liquid
6.3.3.1.3. FoundationOne Heme
6.3.4. Recent
Developments and Future Outlook
6.4. NeoGenomics
Laboratories
6.4.1. Company
Overview
6.4.2. Financial
Information
6.4.3. Product
/ Service Portfolio
6.4.3.1. Biomarkers
Testing Portfolio
6.4.3.1.1. NeoTYPE Discovery Profile for Solid
Tumors
6.4.3.1.2. MSI Analysis / MMR Panel by IHC
6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte
Panel
6.4.4. Recent
Developments and Future Outlook
6.5. Novogene
6.5.1. Company
Overview
6.5.2. Product
/ Service Portfolio
6.5.2.1. Biomarkers
Testing Portfolio
6.5.2.1.1. NovoPM Cancer Panel
6.5.2.1.2. NovoPM TMB
6.5.2.1.3. NovoPM bTMB
6.5.2.1.4. NovoPM MSI
6.5.3. Recent
Developments and Future Outlook
6.6. Q2
Solutions
6.6.1. Company
Overview
6.6.2. Product
/ Service Portfolio
6.6.2.1. Biomarkers
Testing Portfolio
6.6.2.1.1. TMB Assay
6.6.2.1.2. MSI Assay
6.6.2.1.3. TILs Testing
6.6.3. Recent
Developments and Future Outlook
6.7. Personal
Genome Diagnostics
6.7.1. Company
Overview
6.7.2. Product
/ Service Portfolio
6.7.2.1. Biomarkers
Testing Portfolio
6.7.2.1.1. PGDx elio Tissue Complete Assay
6.7.2.1.2. PlasmaSELECT-R 64
6.7.2.1.3. CancerXOME-R
6.7.2.1.4. CancerSELECT-R 125
6.7.2.1.5. MutatorDETECT
6.7.3. Recent
Developments and Future Outlook
6.8. Shenzhen
Yuce Biotechnology
6.8.1. Company
Overview
6.8.2. Product
/ Service Portfolio
6.8.2.1. Biomarkers
Testing Portfolio
6.8.2.1.1. YuceOne Plus
6.8.2.1.2. YuceOne ICIs
6.8.2.1.3. ct-DNA TMB
6.8.2.1.4. Microsatellite (MSI) Test
6.8.3. Recent
Developments and Future Outlook
7 PUBLICATION ANALYSIS
7.1. Chapter
Overview
7.2. Methodology
7.3. Cancer
Biomarkers: List of Publications
7.3.1. Analysis
by Year of Publication, 2016-2019
7.3.2. Analysis
by Year of Publication and Type of Biomarker
7.3.3. Analysis
by Year of Publication and Disease Indication
7.3.4. Analysis
by Year of Publication and Analytical Technique Used
7.3.5. Analysis
by Year of Publication and Type of Cancer Therapy
7.3.6. Most
Popular Journals
7.4. Publication
Analysis: TMB
7.4.1. Analysis
by Year of Publication, 2016-2019
7.4.2. Analysis
by Disease Indication
7.4.3. Analysis
by Analytical Technique Used
7.4.4. Most
Popular Journals
7.5. Publication
Analysis: MSI / MMR
7.5.1. Analysis
by Year of Publication, 2016-2019
7.5.2. Analysis
by Disease Indication
7.5.3. Analysis
by Analytical Technique Used
7.5.4. Most
Popular Journals
7.6. Publication
Analysis: TILs
7.6.1. Analysis
by Year of Publication, 2016-2019
7.6.2. Analysis
by Disease Indication
7.6.3. Analysis
by Analytical Technique Used
7.6.4. Most
Popular Journals
8 INNOVATIVE DESIGNS FOR BIOMARKER-BASED
CLINICAL TRIALS
8.1. Background
and Context
8.2. Biomarker-based
Clinical Trial Designs
8.2.1. Enrichment
Design
8.2.2. All-Comers
Design
8.2.3. Mixture
/ Hybrid Design
8.2.4. Adaptive
Design
8.3 Regulatory
Considerations
9 CLINICAL TRIAL ANALYSIS
9.1. Chapter
Overview
9.2. Methodology
9.3. Cancer
Biomarkers: List of Clinical Trials
9.4. Clinical
Trial Analysis: TMB
9.4.1. Analysis
by Trial Registration Year
9.4.2. Analysis
by Trial Recruitment Status
9.4.3. Analysis
by Trial Phase
9.4.4. Analysis
by Trial Design
9.4.5. Analysis
by Disease Indication
9.4.6. Most
Active Players
9.4.7. Analysis
by Number of Clinical Trials and Geography
9.4.8. Analysis
by Number of Clinical Trials, Trial Phase and Recruitment Status
9.4.9. Analysis
by Enrolled Patient Population and Geography
9.4.10. Analysis
by Enrolled Patient Population, Trial Phase and Recruitment Status
9.5. Clinical
Trial Analysis: MSI / MMR
9.5.1. Analysis
by Trial Registration Year
9.5.2. Analysis
by Trial Recruitment Status
9.5.3. Analysis
by Trial Phase
9.5.4. Analysis
by Trial Design
9.5.5. Analysis
by Disease Indication
9.5.6. Most
Active Players
9.5.7. Analysis
by Number of Clinical Trials and Geography
9.5.8. Analysis
by Number of Clinical Trials, Trial Phase and Recruitment Status
9.5.9. Analysis
by Enrolled Patient Population and Geography
9.5.10. Analysis
by Enrolled Patient Population, Trial Phase and Recruitment Status
9.6. Clinical
Trial Analysis: TILs
9.6.1. Analysis
by Trial Registration Year
9.6.2. Analysis
by Trial Recruitment Status
9.6.3. Analysis
by Trial Phase
9.6.4. Analysis
by Trial Design
9.6.5. Analysis
by Disease Indication
9.6.6. Most
Active Players
9.6.7. Analysis
by Number of Clinical Trials and Geography
9.6.8. Analysis
by Number of Clinical Trials, Trial Phase and Recruitment Status
9.6.9. Analysis
by Enrolled Patient Population and Geography
9.6.10. Analysis
by Enrolled Patient Population, Trial Phase and Recruitment Status
9.7 Clinical
Trials Summary: Analysis by Registration Year and Biomarker
9.8 Clinical
Trials Summary: Analysis by Registration Year and Disease Indication
10. MARKET FORECAST
10.1. Chapter
Overview
10.2. Assumptions
10.3 Forecast
Methodology
10.4. Global
Cancer Biomarkers Testing Market, 2019-2030 (By Value)
10.5. Global
Cancer Biomarkers Testing Market, 2019-2030 (By Volume)
10.6. Cancer
Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Value)
10.7. Cancer
Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Volume)
10.8. Cancer
Biomarkers Testing Market: Distribution by Type of Test, 2019-2030 (By Value)
10.8.1. Cancer Biomarkers Testing Market: Distribution by Type of test and
Geography, 2019-2030 (By Value)
10.9. Cancer
Biomarkers Testing Market: Distribution by Type of test, 2019-2030 (By Volume)
10.9.1. Cancer Biomarkers Testing Market: Distribution by Type of test and
Geography, 2019-2030 (By Volume)
10.10. Cancer
Biomarkers Testing Market: Distribution by Disease Indication, 2019-2030 (By
Value)
10.11. Cancer
Biomarkers Testing Market: Distribution
by Disease Indication, 2019-2030 (By Volume)
10.12. Cancer
Biomarkers Testing Market: Distribution
by Analytical Technique, 2019-2030 (By Value)
10.12.1. Cancer Biomarkers Testing Market:
Distribution by Analytical Technique and Geography, 2019- 2030 (By Value)
10.13. Cancer
Biomarkers Testing Market: Distribution by Analytical Technique, 2019-2030 (By
Volume)
10.13.1. Cancer Biomarkers Testing Market:
Distribution by Analytical Technique and Geography, 2019-2030 (By Volume)
10.14. Cancer
Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Value)
10.15. Cancer
Biomarkers Testing Market for TMB, 2019-2030 (By Value)
10.15.1. Cancer Biomarkers Testing Market for TMB:
Distribution by Geography, 2019-2030 (By Value)
10.15.2. Cancer Biomarkers Testing Market for TMB:
Distribution by Cancer Indication, 2019-2030 (By Value)
10.15.3. Cancer Biomarkers Testing Market for TMB:
Distribution by Analytical Technique, 2019-2030 (By Value)
10.15.4. Cancer Biomarkers Testing Market for TMB:
Distribution by Type of test, 2019-2030 (By Value)
10.16. Cancer
Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Value)
10.16.1. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Geography, 2019-2030 (By Value)
10.16.2. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Cancer Indication, 2019-2030 (By Value)
10.16.3. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Analytical Technique, 2019-2030 (By Value)
10.16.4. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Type of test, 2019-2030 (By Value)
10.17. Cancer
Biomarkers Testing Market for TILs, 2019-2030 (By Value)
10.17.1. Cancer Biomarkers Testing Market for TILs:
Distribution by Geography, 2019-2030 (By Value)
10.17.2. Cancer Biomarkers Testing Market for TILs:
Distribution by Cancer Indication, 2019-2030 (By Value)
10.17.3. Cancer Biomarkers Testing Market for TILs:
Distribution by Analytical Technique, 2019-2030 (By Value)
10.17.4. Cancer Biomarkers Testing Market for TILs:
Distribution by Type of test, 2019-2030 (By Value)
10.18. Cancer
Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Volume)
10.19. Cancer
Biomarkers Testing Market for TMB, 2019-2030 (By Volume)
10.19.1. Cancer Biomarkers Testing Market for TMB:
Distribution by Geography, 2019-2030 (By Volume)
10.19.2. Cancer Biomarkers Testing Market for TMB: Distribution
by Cancer Indication, 2019-2030 (By Volume)
10.19.3. Cancer Biomarkers Testing Market for TMB:
Distribution by Analytical Technique, 2019-2030 (By Volume)
10.19.4. Cancer Biomarkers Testing Market for TMB:
Distribution by Type of test, 2019-2030 (By Volume)
10.20. Cancer
Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Volume)
10.20.1. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Geography, 2019-2030 (By Volume)
10.20.2. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Cancer Indication, 2019-2030 (By Volume)
10.20.3. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Analytical Technique, 2019-2030 (By Volume)
10.20.4. Cancer Biomarkers Testing Market for MSI /
MMR: Distribution by Type of test, 2019-2030 (By Volume)
10.21. Cancer
Biomarkers Testing Market for TILs, 2019-2030 (By Volume)
10.21.1. Cancer Biomarkers Testing Market for TILs:
Distribution by Geography, 2019-2030 (By Volume)
10.21.2. Cancer Biomarkers Testing Market for TILs: Distribution
by Cancer Indication, 2019-2030 (By Volume)
10.21.3. Cancer Biomarkers Testing Market for TILs:
Distribution by Analytical Technique, 2019-2030 (By Value)
10.21.4. Cancer Biomarkers Testing Market for TILs:
Distribution by Type of Test, 2019-2030 (By Value)
11. FUTURE GROWTH OPPORTUNITIES
11.1. Chapter
Overview
11.1.1. Increasing
Focus on Precision Medicine
11.1.2. Rise
in Number of Biomarker-based Clinical Trials
11.1.3. Emerging
Technologies for Biomarker Assessment
11.1.4. Development
of Companion Diagnostic Products
11.1.5. Other
Opportunities
12. CASE STUDY:
ANALYSIS OF NEEDS OF STAKEHOLDERS IN THE COMPANION DIAGNOSTICS INDUSTRY
12.1. Chapter
Overview
12.2. Companion
Diagnostics: Needs of Different Stakeholders
12.3. Comparison
of Needs of Various Stakeholders
12.3.1. Needs
of Drug Developers
12.3.2. Needs
of Companion Diagnostics Developers
12.3.3. Needs
of Regulatory Authorities
12.3.4. Needs
of Testing Laboratories
12.3.5. Needs
of Payers / Insurance Providers
12.3.6. Needs
of Physicians
12.3.7. Needs
of Patients
13. CASE STUDY:
ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY
13.1. Chapter
Overview
13.2. Companion
Diagnostics: Components of the Value Chain
13.3. Companion
Diagnostics Value Chain: Cost Distribution
13.3.1. Companion
Diagnostics Value Chain: Costs Associated with Research and Product Development
13.3.2. Companion Diagnostics Value Chain: Costs Associated with Costs
Associated with Manufacturing and Assembly
13.3.3. Companion Diagnostics Value Chain: Costs Associated with Clinical
Trials, FDA Approval and Other Administrative Tasks
13.3.4. Companion Diagnostics Value Chain: Costs Associated with Payer
Negotiation and KoL Engagement
13.3.5. Companion
Diagnostics Value Chain: Costs Associated with Marketing and Sales
14. CLINICAL RESEARCH ON CANCER BIOMARKERS:
A BIG PHARMA PERSPECTIVE
14.1. Chapter
Overview
14.2. Methodology
14.3. Clinical
Trial Analysis
14.3.1. List
of Likely Drug Candidates for IVD Developers
14.4. Cumulative
Distribution of Biomarker-based Trials by Registration Year, 2016-2019
14.4.1. Analysis
of Biomarker-based Trials of Most Popular Biomarkers
14.4.2. Analysis
of Biomarker-based Trials of Moderately Popular Biomarkers
14.4.3. Analysis
of Biomarker-based Trials of Less Popular / Other Biomarkers
14.4.4. Word
Cloud of Other Emerging Biomarkers
14.4.5. Cumulative
Distribution of Trials by Registration year and Most Popular Biomarkers
14.4.6. Cumulative
Distribution of Trials by Registration year and Moderately Popular Biomarkers
14.4.7. Cumulative
Distribution of Trials by Registration year and Less Popular / Other Biomarkers
14.5. Distribution
of Biomarker-based Trials by Most Popular Indications
14.5.1. Distribution
of Biomarker-based Trials by Moderately Popular Indications
14.5.2. Distribution
of Biomarker-based Trials by Less Popular / Other Indications
14.5.3. Word
Cloud of Other Emerging Indications in Biomarker-based Clinical Trials
14.5.4. Cumulative
Distribution of Trials by Registration year and Most Popular Indication
14.5.5. Cumulative
Distribution of Trials by Registration year and Moderately Popular Indications
14.5.6. Cumulative
Distribution of Trials by Registration year and Less Popular / Other
Indications
14.6. Analysis
of Biomarker-based Trials by Phase of Development
14.6.1. Analysis
of Biomarker-based Trials by Phase of Development and Most Popular Biomarkers
14.6.2. Analysis of Biomarker-based Trials by Phase of Development and
Moderately Popular Biomarkers
14.6.3. Analysis of Biomarker-based Trials by Phase of Development and Less
Popular and Other Biomarkers
14.6.4. Analysis
of Biomarker-based Trials by Phase of Development and Most Popular Indications
14.6.5. Analysis
of Biomarker-based Trials by Phase of Development and Moderately Popular
Indications
14.6.6. Analysis of Biomarker-based Trials by Phase of Development and Less
Popular and Other Indications
14.7. Analysis
of Biomarker-based Trials by Sponsor
14.7.1. Analysis
of Biomarker-based Trials by Sponsor and Most Popular Biomarkers
14.7.2. Analysis
of Biomarker-based Trials by Sponsor and Moderately Popular Biomarkers
14.7.3. Analysis
of Biomarker-based Trials by Sponsor and Most Popular Indications
14.7.4. Analysis
of Biomarker-based Trials by Sponsor and Moderately Popular Indications
14.8. Analysis
of Biomarker-based Trials by Recruitment Status
14.9. Analysis
of Biomarker-based Trials by Therapy Design
14.10. Analysis
of Biomarker-based Trials by Geography
14.10.1. Analysis of Biomarker-based Trials by Trial
Phase and Recruitment Status
14.11. Clinical
Trials Summary: Analysis by Biomarker and Most Popular Indications
14.12. Clinical
Trials Summary: Analysis by Biomarker and Moderately Popular Indications
14.13. Clinical
Trials Summary: Analysis by Biomarker and Other Emerging Indications
17. APPENDIX
2: LIST OF COMPANIES AND ORGANIZATIONS
Contact
Details
Gaurav
Chaudhary
+1
(415) 800 3415
